Skip to content
lifestyle.eastmnweeklynews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nxera Pharma
Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026
November 4, 2026
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
November 4, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026
October 30, 2026
Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets
October 28, 2026
Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy
October 22, 2026
Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets
October 14, 2026
Nxera Announces Successful Resolution of miniG Patent Infringement Action
October 1, 2026
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
September 3, 2026
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer’s Cognition
August 26, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
August 7, 2026
1
2
Next Page
→